Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; WAINUA for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults; and SPINRAZA for pediatric and adult patients with spinal muscular atrophy (SMA). It also provides QALSODY for the treatment of Amyotrophic Lateral Sclerosis (ALS); TEGSEDI for the treatment of ATTRv-PN in adults; and WAYLIVRA for treatment for FCS and familial partial lipodystrophy. It also develops products under Phase 3 clinical trials, such as Olezarsen for patients with hypertriglyceridemia (SHTG) and cardiovascular disease (CVD); Donidalorsen for patients with hereditary angioedema; and Zilganerse, a potential treatment for people with genetically confirmed Alexander disease, as well as ION582 that has completed Phase 2 clinical trial for the potential treatment of AS, a rare genetic neurological disease. In addition, the company develops Eplontersen to degrade mutant and wild-type TTR mRNA through binding to the TTR mRNA; Pelacarsen to inhibit the production of apolipoprotein(a) in the liver to offer a direct approach for reducing lipoprotein(a); Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus; Sefaxersen to reduce the production of complement factor B and lower activation of the alternative complement pathway; and Ulefnersen to reduce the production of the fused in sarcoma, as well as other mid-stage pipeline investigational medicines. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with GSK, AstraZeneca, Novartis, and Roche, as well as with Metagenomi. The company was incorporated in 1989 and is headquartered in Carlsbad, California.

Ionis Pharmaceuticals, Inc.

Stifel Nicolaus analyst Paul Matteis maintained a Hold rating on Ionis Pharmaceuticals today and set a price target of $68.00. According to TipRank...

Ionis Pharmaceuticals (IONS) Receives a Hold from Stifel Nicolaus

Insiders have been trading these 5 stocks: (($MKC)), (($WAB)), (($ECL)), (($IONS)) and (($FAST)). Here is a breakdown of their recent trades and th...

McCormick, Wabtec, Ecolab, Ionis, Fastenal Insider Shock

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Boston Scientific (BSX), Ionis Pharmaceuticals (IONS) and Conmed ...

Analysts Conflicted on These Healthcare Names: Boston Scientific (BSX), Ionis Pharmaceuticals (IONS) and Conmed (CNMD)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Ionis Pharmaceuticals (IONS) and Avantor (AVTR). I...

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Ionis Pharmaceuticals (IONS) and Avantor (AVTR)

Ionis Pharmaceuticals Inc. ($IONS) announced an update on their ongoing clinical study. Ionis Pharmaceuticals, Inc. is running a Phase 3 study call...

Ionis Expands Rare Disease Reach With Pediatric FCS Trial for Olezarsen

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Option Care Health (OPCH) and Ionis Pharmaceuticals ...

Analysts Are Bullish on Top Healthcare Stocks: Option Care Health (OPCH), Ionis Pharmaceuticals (IONS)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Arcus Biosciences (RCUS) and Ionis Pharmaceuticals (...

Analysts Offer Insights on Healthcare Companies: Arcus Biosciences (RCUS) and Ionis Pharmaceuticals (IONS)

Morgan Stanley analyst Michael Ulz maintained a Buy rating on Ionis Pharmaceuticals today and set a price target of $110.00. According to TipRanks,...

Morgan Stanley Sticks to Its Buy Rating for Ionis Pharmaceuticals (IONS)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Claritev (CTEV), Ionis Pharmaceuticals (IONS) and Ar...

Analysts Offer Insights on Healthcare Companies: Claritev (CTEV), Ionis Pharmaceuticals (IONS) and Arrowhead Pharmaceuticals (ARWR)

In a report released today, Jessica Fye from J.P. Morgan maintained a Buy rating on Ionis Pharmaceuticals, with a price target of $72.00. According...

J.P. Morgan Keeps Their Buy Rating on Ionis Pharmaceuticals (IONS)

Wells Fargo analyst maintained a Buy rating on Ionis Pharmaceuticals today and set a price target of $100.00. In addition to Wells Fargo, Ionis Pha...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	IONS	$56.56	+3.80%	2.01M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	IONS	$56.56	+3.8%	2.01M
3
4
5
6

IONS

IONS

Get Ionis Pharmaceuticals, Inc. Data in Excel

Get Ionis Pharmaceuticals, Inc. Data in Excel